Progranulin mutations and amyotrophic lateral sclerosis or amyotrophic lateral sclerosis-frontotemporal dementia phenotypes.

Laboratory of Neurogenetics, National Institute of Aging, NIH, Bethesda, Maryland, USA.
Journal of neurology, neurosurgery, and psychiatry (Impact Factor: 4.87). 08/2007; 78(7):754-6. DOI: 10.1136/jnnp.2006.109553
Source: PubMed

ABSTRACT Mutations in the progranulin (PGRN) gene were recently described as the cause of ubiquitin positive frontotemporal dementia (FTD). Clinical and pathological overlap between amyotrophic lateral sclerosis (ALS) and FTD prompted us to screen PGRN in patients with ALS and ALS-FTD.
The PGRN gene was sequenced in 272 cases of sporadic ALS, 40 cases of familial ALS and in 49 patients with ALS-FTD.
Missense changes were identified in an ALS-FTD patient (p.S120Y) and in a single case of limb onset sporadic ALS (p.T182M), although the pathogenicity of these variants remains unclear.
PGRN mutations are not a common cause of ALS phenotypes.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Frontotemporal lobar degeneration (FTLD) is associated with cytoplasmic or nuclear deposition of the TAR DNA binding protein 43 (TDP-43). Haploinsufficiency of progranulin (GRN) is a major genetic risk for FTLD associated with TDP-43 deposition. Therefore understanding the mechanisms, which control cellular expression of GRN is required not only to understand disease etiology but also for the development of potential therapeutic strategies. We identified different GRN transcripts with short (38-93 nucleotides) or long (219 nucleotides) 5'-untranslated regions (UTR) and demonstrate a cellular mechanism, which represses translation of GRN mRNAs with long 5'-UTRs. The long 5'-UTR of GRN mRNA contains an upstream open reading frame (uORF), which is absent in all shorter transcripts. Since such UTRs can be involved in translational control as well as mRNA stability, we compared the expression of GRN in cells expressing cDNAs with and without 5'-UTRs. This revealed a selective repression of GRN translation and a reduction of mRNA levels by the 219 nucleotide long 5'-UTR. The specific ability of this GRN 5'-UTR to repress protein expression was further confirmed by its transfer to an independent reporter. Deletion analysis identified a short stretch between nucleotides 76 and 125 containing two start codons within one uORF, which is required and sufficient for repression of protein expression. Mutagenesis of the two AUG codons within the uORF is sufficient to reduce translational repression. These findings therefore suggest a mechanism, where initiating ribosomes are either stalled at the AUGs of the uORF or leaky scanning leads to inefficient translation of GRN.
    Journal of Biological Chemistry 07/2014; 289(37). · 4.60 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: One of the most interesting findings in the field of neurodegeneration in recent years is tfche discovery of a genetic mutation in the C9orf72 gene, the most common mutation found to be causative of sporadic and familial frontotemporal lobar degeneration (FTLD), amyotrophic lateral sclerosis (ALS) and concomitant FTD-ALS (DeJesus-Hernandez et al., 2011b; Renton et al., 2011). While clinical and molecular data, such as the identification of TDP-43 being a common pathological protein (Neumann et al., 2006) have hinted at such a link for years, the identification of what was formally known as "the chromosome 9 FTLD-ALS gene" has provided a foundation for better understanding of the relationship between the two. Indeed, it is now recognized that ALS and FTLD-TDP represent a disease spectrum. In this review, we will discuss the current genetic and pathological features of the FTLD-ALS spectrum.
    Experimental Neurology 06/2014; · 4.62 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Frontotemporal dementias are neurodegenerative diseases in which symptoms of frontal and/or temporal lobe disease are the first signs of the illness, and as the diseases progress, they resemble a focal left hemisphere process such as stroke or traumatic brain injury, even more than a neurodegenerative disease. Over time, some patients develop a more generalized dementia. Four clinical subtypes characterize the predominant presentations of this illness: behavioral or frontal variant FTD, progressive nonfluent aphasia, semantic dementia, and logopenic primary progressive aphasia. These clinical variants correlate with regional patterns of atrophy on brain imaging studies such as MRI and PET scanning, as well as with biochemical and molecular genetic variants of the disorder. The treatment is as yet only symptomatic, but advances in molecular genetics promise new therapies.
    Neuropsychiatric Disease and Treatment 06/2014; 10:1045-55. · 2.00 Impact Factor

Full-text (2 Sources)

Available from
May 22, 2014